INTRODUCTION {#s1}
============

Prostate cancer (PCa) is now thought to be one of the most commonly diagnosed malignant tumors in old men throughout the world, and the second cause of cancer in males. It accounted for approximately 233,000 (27%) new cases and 30,000 deaths in the United States in 2014 \[[@R1]\]. The global incidence of PCa has increased annually. The etiology of PCa is largely unknown. Several factors have been suggested to be strongly associated with the increased risk, including ethnic origin, family history, hormonal status, dietary structure and age \[[@R2]\].

Low levels of vitamin D are considered to be a risk factor for PCa \[[@R3]\]. *In vitro* experiments suggested that vitamin D inhabits the growth and differentiation of prostate cancer cells, promotes cell apoptosis. It can also inhabit the invasion, metabolism and angiogenesis of tumor cell \[[@R3]\]. A clinical trial of PCa patients showed that calcitriol, analogue of vitamin D can significantly reduce the prostate specical antigen (PSA) level, and improve the patients survival rate \[[@R4]\].

The anticancer effect of vitamin D is activated mainly through the vitamin D receptor (*VDR*) \[[@R5]\]. 1,25-Dihydroxy vitamin D3 (1,25(OH)~2~D~3~), the active form of vitamin D, binds to *VDR* and form a heterodimer complex, which subsequently binds to the vitamin D response element and down-regulate the transcription of numerous genes that stimulating the cell growth and differentiation \[[@R6]\].

Several single nucleotide polymorphisms (SNPs) of *VDR* gene were reported to be associated with risk of PCa \[[@R7]\]. *Fok I* variant (rs10735810) located in exon 2 of *VDR* gene is one of the most extensively studied SNPs \[[@R8]\]. It could result in a frame-shift mutation in the expression of VDR. It has been reported that f allele results in three amino acids longer VDR than the F allele, and extensive researches indicate that f allele is less effective than the F allele in transcription activity and transactivation of the 1,25(OH)~2~D~3~ signal \[[@R8]\]. Recent studies have shown that *Fok I* polymorphism might accelerate the progression of PCa. However, the results are disputable and contradictory \[[@R9], [@R10]\], as it might be underpowered for individual study. Therefore, we performed this meta-analysis to draw a more precise conclusion based on the published literature.

RESULTS {#s2}
=======

Characteristics of studies included in this meta-analysis {#s2_1}
---------------------------------------------------------

A total of 277 potentially relevant studies were identified following the searching strategy. 27 studies \[[@R2], [@R6], [@R7], [@R9], [@R10], [@R12]-[@R32]\] were finally included in this meta-analysis according to the inclusion criteria (Figure [1](#F1){ref-type="fig"}). Publication years ranged from 1999 to 2015, the number of cases varied from 28 to 1,518, and the number of controls varied from 56 to 1,432 (Table [1](#T1){ref-type="table"}). The distribution of genotype frequency in the control groups was in accordance with the HWE for almost studies, except two studies \[[@R9], [@R15]. in which source of controls was hospital-based. As a result, data for our meta-analysis were available from 27 studies with a total of 10,468 cases and 10,400 controls. The eligible studies were assessed by the NOS. Each of the studies scored morethan 4, which suggested that all of them are of high quality researches (Table [1](#T1){ref-type="table"}).

![Study flowchart for the process of selecting the final 27 studies](oncotarget-07-77878-g001){#F1}

###### Characteristics and quality assessment of the studies included in this meta-analysis

  Study ID        Year   Country          Ethnicity   Genotyping method   Source of controls   Total sample size (case/control)   HWE   Quality indicators from NOS
  --------------- ------ ---------------- ----------- ------------------- -------------------- ---------------------------------- ----- -----------------------------
  Atoum           2015   Jordan           Asian       TaqMan              PB                   124/100                            Y     6
  Bai             2009   China            Asian       PCR-RFLP            HB                   122/130                            Y     6
  Bodiwala        2004   UK               Caucasian   PCR-RFLP            HB/BPH               368/243                            Y     6
  Chen            2001   China            Asian       PCR-RFLP            HB                   101/145                            N     5
  Cheteri         2004   USA              Caucasian   PCR-RFLP            PB                   552/521                            Y     6
  Chokkalingam    2001   China            Asian       PCR-RFLP            PB                   187/302                            Y     6
  Cicek           2006   USA              Mixed       PCR-RFLP            PB                   439/479                            Y     6
  Correa-Cerro    1999   Germany/France   Caucasian   PCR-RFLP            HB                   118/89                             Y     6
  Hayes           2005   Australia        Caucasian   DGGE\*              PB                   811/713                            Y     7
  Holick          2007   USA              Caucasian   SNPlex              PB                   583/552                            Y     6
  Holt            2009   USA              Caucasian   SNPlex              PB                   705/716                            Y     6
  Huang           2006   China            Asian       PCR-RFLP            HB/BPH               416/502                            Y     6
  Jiang           2013   China            Asian       PCR-RFLP            PB                   100/108                            Y     6
  John            2005   USA              Caucasian   TaqMan              PB                   425/437                            Y     6
  Li              2007   USA              Caucasian   PCR-RFLP            PB                   1010/1432                          Y     8
  Luscombe        2001   UK               Caucasian   PCR-RFLP            BPH                  209/154                            Y     6
  Mikhak          2007   USA              Caucasian   TaqMan              PB                   670/673                            Y     7
  Mishra          2005   India            Asian       PCR-RFLP            HB                   147/128                            Y     6
  Oakley-Grivan   2004   USA              Mixed       PCR-RFLP            PB                   345/292                            Y     6
  Oh              2013   Korea            Asian       IGGGS\#             BPH                  272/173                            Y     6
  Rowland         2013   USA              Mixed       TaqMan              PB                   1518/1070                          Y     7
  Ruan            2009   China            Asian       PCR-RFLP            BPH                  100/100                            Y     5
  Rukin           2007   UK               Caucasian   Pyrosequencing      BPH                  430/320                            Y     6
  Tayeb           2004   UK               Caucasian   PCR-RFLP            BPH                  28/56                              Y     6
  Torkko          2008   USA              Caucasian   TaqMan              PB                   585/761                            Y     6
  Yang            2004   China            Asian       PCR-RFLP            PB                   80/96                              Y     5
  Yousaf          2014   Pakistani        Asian       PCR-RFLP            HB                   41/108                             N     6

Abbreviations: HWE, Hardy-Weinberg equilibrium; PB, population-based; HB, hospital-based; BPH, Benign Prostate Hyperplasia; RFLP, restriction fragment length polymorphism; DGGE, denaturing gradient gel electrophoresis; IGGGS, Illumina Golden Gate genotyping system

Meta-analysis results {#s2_2}
---------------------

The results of overall analysis are showed in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. The pooled results indicated that *Fok I* polymorphism is not associated with the PCa risk in the overall populations (ff vs. FF: OR=1.07, 95%CI=0.98-1.16, p=0.131; Ff vs. FF: OR=1.03, 95%CI=0.97-1.10, p=1.05; Ff/ff vs. FF: OR= 1.04, 95%CI= 0.98-1.10, p=0.173; ff vs. FF/Ff: OR=1.04, 95%CI=0.96-1.12, p=0.318; f vs. F allele: OR=1.03, 95%CI=0.99-1.07, p=0.138). (Table [2](#T2){ref-type="table"}).

###### Results of the association between *Fok I* polymorphism and PCa risk in the whole population

  Comparison        Studies   Overall effect       Heterogeneity   Public bias                         
  ----------------- --------- -------------------- --------------- ------------- ----- ------- ------- -------
  **ff vs FF**      27        1.07 \[0.98-1.16\]   1.51            0.131         14%   0.255   0.087   0.118
  **Ff vs FF**      27        1.03 \[0.97-1.10\]   1.05            0.296         0%    0.809   0.402   0.866
  **ff+Ff vs FF**   27        1.04 \[0.98-1.10\]   1.36            0.173         0%    0.475   0.133   0.322
  **ff vs FF+Ff**   27        1.04 \[0.96-1.12\]   1               0.318         13%   0.274   0.227   0.138
  **f vs F**        27        1.03 \[0.99-1.07\]   1.48            0.138         27%   0.102   0.027   0.101

![Forest plots to estimate the association of VDR Fok I polymorphism with PCa in the subgroup analysis of ethnicity\
**A.** Homozygote model (ff vs. FF). **B.** Allelic frequency model (f vs. F allele).](oncotarget-07-77878-g002){#F2}

For the subgroup analysis of ethnicity stratification. Significantly increased risk of PCa was detected in Caucasian populations in the comparison of homozygote model (ff vs. FF: OR=1.107, 95%CI=1.005-1.219, p=0.04), dominant model (Ff/ff vs. FF: OR=1.079, 95%CI=1.010-1.152, p=0.024) and allele-frequency genetic model (f vs. F allele: OR=1.054, 95%CI=1.006-1.103, p=0.026)(Table [3](#T3){ref-type="table"} & Figure [2](#F2){ref-type="fig"}). However, when 11 studies conducted in Asian populations and 2 studies in African populations were analyzed, no significant associations were found between *Fok I* polymorphism and the susceptibility to PCa (Table [3](#T3){ref-type="table"}).

###### Results of the association between *Fok I* polymorphism and PCa risk in different ethnicities

  Comparison      Studies   Overall effect          Heterogeneity   Public bias                         
  --------------- --------- ----------------------- --------------- ------------- ----- ------- ------- -------
  **Asian**                                                                                             
  ff vs FF        11        0.940 \[0.771-1.150\]   0.58            0.561         48%   0.037   0.876   0.901
  Ff vs FF        11        1.032 \[0.880-1.210\]   0.39            0.696         18%   0.276   0.721   0.819
  Ff/ff vs FF     11        1.003 \[0.864-1.166\]   0.04            0.964         43%   0.063   0.213   0.635
  ff vs FF/Ff     11        0.944 \[0.797-1.117\]   0.67            0.501         41%   0.078   0.876   0.95
  f vs F          11        0.983 \[0.892-1.082\]   0.36            0.722         59%   0.007   0.213   0.637
  **Caucasian**                                                                                         
  ff vs FF        15        1.107 \[1.005-1.219\]   2.06            0.04          0%    0.769   0.138   0.034
  Ff vs FF        15        1.070 \[0.998-1.147\]   1.9             0.058         0%    0.973   0.488   0.562
  Ff/ff vs FF     15        1.079 \[1.010-1.152\]   2.25            0.024         0%    0.915   0.488   0.176
  ff vs FF/Ff     15        1.057 \[0.969-1.152\]   1.24            0.214         0%    0.694   0.276   0.089
  f vs F          15        1.054 \[1.006-1.103\]   2.23            0.026         0%    0.679   0.428   0.06
  **African**                                                                                           
  ff vs FF        2         1.165 \[0.603-2.249\]   0.45            0.65          0%    0.406   1       \-
  Ff vs FF        2         0.861 \[0.646-1.148\]   1.02            0.309         73%   0.055   1       \-
  Ff/ff vs FF     2         0.899 \[0.673-1.173\]   0.83            0.405         75%   0.045   1       \-
  ff vs FF/Ff     2         1.215 \[0.633-2.330\]   0.58            0.559         0%    0.554   1       \-
  f vs F          2         0.945 \[0.751-1.189\]   0.48            0.631         73%   0.052   1       \-

For the stratified analysis of source of controls. We found that *Fok I* polymorphism could significantly increase the risk of PCa in the subgroup of population-based controls in homozygote model (ff vs. FF: OR=1.112, 95%CI=1.011-1.223, p=0.029) and allele-frequency genetic model (f vs. F allele: OR=1.005-1.099, p=0.03) (Table [4](#T4){ref-type="table"} & Figure [3](#F3){ref-type="fig"}). Meanwhile, no significantly increased risk was observed in the subgroups of hospital-based or BPH controls (Table [4](#T4){ref-type="table"}).

![Forest plots to estimate the association of VDR Fok I polymorphism with PCa in the subgroup analysis of source of controls\
**A.** Homozygote model (ff vs. FF). **B.** Allelic frequency model (f vs. F allele).](oncotarget-07-77878-g003){#F3}

###### Results of the association between *Fok I* polymorphism and PCa risk in different source of controls

  Comparison             Studies   Overall effect              Heterogeneity   Public bias                         
  ---------------------- --------- --------------------------- --------------- ------------- ----- ------- ------- -------
  **Population-based**                                                                                             
  ff vs FF               15        **1.112 \[1.011-1.223\]**   2.19            0.029         0%    0.958   0.434   0.186
  Ff vs FF               15        1.051\[0.983-1.124\]        1.45            0.148         0%    0.809   0.202   0.126
  Ff/ff vs FF            15        1.064 \[0.998-1.133\]       1.9             0.058         0%    0.811   0.174   0.053
  ff vs FF/Ff            15        1.074 \[0.984-1.171\]       1.6             0.109         0%    0.935   0.773   0.367
  f vs F                 15        **1.051 \[1.005-1.099\]**   2.17            0.03          0%    0.833   1.108   0.016
  **Hospital-based**                                                                                               
  ff vs FF               6         0.931 \[0.711-1.219\]       0.52            0.062         52%   0.063   0.452   0.524
  Ff vs FF               5         1.088 \[0.866-1.337\]       0.81            0.42          47%   0.11    0.806   0.419
  Ff/ff vs FF            6         1.045 \[0.862-1.268\]       0.45            0.653         59%   0.033   0.452   0.999
  ff vs FF/Ff            6         0.910 \[0.718-1.152\]       0.79            0.432         46%   0.103   1       0.642
  f vs F                 6         0.992 \[0.871-1.129\]       0.13            0.897         69%   0.006   1       0.973
  **BPH**                                                                                                          
  ff vs FF               7         0.941 \[0.982-1.159\]       0.55            0.584         48%   0.071   0.548   0.077
  Ff vs FF               7         1.030 \[0.861-1.231\]       0.32            0.748         0%    0.678   0.23    0.025
  Ff/ff vs FF            7         1.001 \[0.846-1.183\]       0.01            0.994         26%   0.231   0.368   0.037
  ff vs FF/Ff            7         0.928 \[0.955-1.107\]       0.85            0.394         35%   0.159   0.368   0.196
  f vs F                 7         0.972 \[0.875-1.081\]       0.52            0.604         54%   0.042   0.368   0.102

In the stratified analysis by genotyping method, there was no significant association in different subgroups, which were stratified into TaqMan, PCR-RFLP, SNPlex and other subgroups. As showed in Table [5](#T5){ref-type="table"}, the pooled outcome showed that the genotyping methods reported in the included studies are both effective and applicative. Among the 27 studies included in our meta-analysis, there were two studies that deviated from HWE in the controls \[[@R9]\], we conducted a subgroup analysis. When the 2 studies excluded, another result obtained, which is similar to the overall analysis (The result was not given).

###### Results of the association between *Fok I* polymorphism and PCa risk in different genotyping method

  Comparison     Studies   Overall effect          Heterogeneity   Public bias                           
  -------------- --------- ----------------------- --------------- ------------- ------- ------- ------- -------
  **PCR-RFLP**                                                                                           
  ff vs FF       17        1.014 \[0.895-1.148\]   0.21            0.83          36%     0.068   0.077   0.182
  Ff vs FF       16        1.063 \[0.970-1.165\]   1.3             0.192         0%      0.611   0.192   0.565
  Ff/ff vs FF    17        1.051 \[0.964-1.146\]   1.13            0.257         27%     0.149   0.053   0.18
  ff vs FF/Ff    17        0.983 \[0.822-1.189\]   0.3             0.766         23%     0.188   0.149   0.176
  f vs F         17        1.020 \[0.960-1.083\]   0.63            0.526         49%     0.012   0.019   0.127
  **TaqMan**                                                                                             
  ff vs FF       5         1.155 \[0.989-1.349\]   1.82            0.068         0%      0.8     1       0.822
  Ff vs FF       5         1.018 \[0.914-1.134\]   0.33            0.74          8%      0.364   0.806   0.785
  Ff/ff vs FF    5         1.047 \[0.946-1.159\]   0.88            0.377         0%      0.676   1       0.854
  ff vs FF/Ff    5         1.131 \[0.981-1.305\]   1.69            0.09          4%      0.385   0.806   0.891
  f vs F         5         1.056 \[0.983-1.136\]   1.49            0.137         0%      0.934   0.806   0.989
  **SNPlex**                                                                                             
  ff vs FF       2         1.120 \[0.866-1.416\]   0.95            0.343         0.00%   0.702   1       \-
  Ff vs FF       2         1.003 \[0.846-1.188\]   0.03            0.976         0%      0.532   1       \-
  Ff/ff vs FF    2         1.031 \[0.983-1.102\]   0.37            0.712         0.00%   0.509   1       \-
  ff vs FF/Ff    2         1.118 \[0.902-1.386\]   1.02            0.309         0.00%   0.884   1       \-
  f vs F         2         1.047 \[0.935-1.171\]   1.48            0.138         0%      0.57    1       \-
  **Others**                                                                                             
  ff vs FF       3         1.013 \[0.802-1.280\]   0.11            0.913         0%      0.475   1       0.607
  Ff vs FF       3         0.995 \[0.828-1.195\]   0.06            0.956         0%      0.803   0.296   0.175
  Ff/ff vs FF    3         0.994 \[0.837-1.182\]   0.06            0.95          0%      0.656   0.296   0.49
  ff vs FF/Ff    3         0.989 \[0.822-1.189\]   0.12            0.904         1%      0.365   1       0.362
  f vs F         3         0.944 \[0.889-1.110\]   0.11            0.91          1%      0.366   1       0.637

A subgroup analysis based on the tumor stages was also conducted to delineate the association in more detail. As presented in Table [6](#T6){ref-type="table"} and Figure [4](#F4){ref-type="fig"}, the pooled results from 6 studies showed that *Fok I* polymorphism is associated with the advanced tumor in homozygote model (ff vs. FF: OR=1.210, 95%CI=1.020-1.437, p=0.029) and allele-frequency genetic model (f vs. F allele: OR=1.085, 95%CI=1.000-1.178, p=0.05). Meanwhile, no significant difference in the genetic variants was detected between localized tumor cases or controls.

###### Results of the association between *Fok I* polymorphism and PCa risk in different tumor stage

  Comparison      Studies   Overall effect              Heterogeneity   Public bias                         
  --------------- --------- --------------------------- --------------- ------------- ----- ------- ------- -------
  **Advanced**                                                                                              
  ff vs FF        6         **1.210 \[1.020-1.437\]**   2.18            0.029         26%   0.24    0.26    0.278
  Ff vs FF        6         1.023 \[0.904-1.158\]       0.36            0.715         0%    0.832   0.707   0.112
  Ff/ff vs FF     6         1.070 \[0.952-1.202\]       1.13            0.259         0%    0.564   0.452   0.164
  ff vs FF/Ff     6         1.194 \[1.022-1.395\]       2.23            0.026         5%    0.388   0.26    0.412
  f vs F          6         **1.085 \[1.000-1.178\]**   1.96            0.05          19%   0.292   0.26    0.271
  **Localized**                                                                                             
  ff vs FF        5         1.002 \[0.817-1.229\]       0.02            0.984         0%    0.628   0.462   0.482
  Ff vs FF        5         1.031 \[0.891-1.193\]       0.41            0.679         0%    0.902   0.462   0.28
  Ff/ff vs FF     5         1.024 \[0.892-1.175\]       0.34            0.737         0%    0.768   0.462   0.384
  ff vs FF/Ff     5         0.980 \[0.814-1.179\]       0.22            0.828         0%    0.731   0.462   0.512
  f vs F          5         1.006 \[0.913-1.108\]       0.12            0.903         0%    0.595   0.806   0.437

![Forest plots to estimate the association of VDR Fok I polymorphism with PCa in the subgroup analysis of tumor stage\
**A.** Homozygote model (ff vs. FF). **B.** Allelic frequency model (f vs. F allele).](oncotarget-07-77878-g004){#F4}

Heterogeneity {#s2_3}
-------------

There was no significant between-study heterogeneity in all the comparison models in the overall analysis (ff vs. FF: p=0.131, I^2^=14%), Ff vs. FF: p=0.105, I^2^=0%; Ff/ff vs. FF: p=0.173, I^2^=0%; ff vs. FF/Ff: p=0.318, I^2^=13%; and f vs. F allele: p=0.138, I^2^=27%) (Table [2](#T2){ref-type="table"}). Thus, fixed-effects estimates would be more appropriate for data analysis.

Publication bias and sensitivity analysis {#s2_4}
-----------------------------------------

The publication bias of literature assessed with both funnel plots and Egger\'s test. As shown in Figure [5](#F5){ref-type="fig"}, it did not reveal any obvious asymmetry in the funnel plots (Figure [5](#F5){ref-type="fig"}). Moreover, the Egger\'s test which was used to provide statistical evidence of publication bias suggested that no evidence of publication bias existed in the overall analysis (p=0.118 for ff vs. FF; p=0.866 for Ff vs. FF; p=0.322 for Ff/ff vs. FF; p=0.138 for ff vs. FF/Ff; and p=0.101 for f vs. F allele) (Table [2](#T2){ref-type="table"}) and almost the subgroup analyses (Table [3](#T3){ref-type="table"}-[6](#T6){ref-type="table"}). Sensitivity analyses showed that omitting individual study from all the analyses did not affect the pooled ORs significantly, no substantial change was detected, indicating that our results were statistically robust (Figure [6](#F6){ref-type="fig"}).

![Begg\'s funnel plots to examine piblishcation bias for reported comparisons of *VDR* gene Fok I polymorphism\
**A.** Overall comparison for the recessive model (ff vs. FF/Ff). **B.** Subgroup analysis of tumor stage for the recessive model (ff vs. FF/Ff).](oncotarget-07-77878-g005){#F5}

![Sensitivity analysis of the comparison in recessive model (ff vs. FF/Ff) in the overall analysis](oncotarget-07-77878-g006){#F6}

DISCUSSION {#s3}
==========

The *VDR* gene has earned special attention because an increasing number of studies have revealed that polymorphisms of the *VDR* gene were associated with the risk of PCa \[[@R33]\]. However, the results across studies have been equivocal \[[@R34], [@R35], [@R36]\]. Previous meta-analyses were performed by Xu et al. in 2014, Guo et al. in 2013 and Yin et al. in 2009 \[[@R34], [@R37], [@R44]\]. Xu et al. and Yin et al. reported the relationship of cancer risk with several *VDR* SNPs including *Fok I*. For the association of *Fok I* polymorphism with PCa, they included 19 studies and 16 studies, respectively. The shortage of these two studies is that they only performed overall analyses without any detailed subgroup analyses. Guo et al. included 22 stuides and conducted the stratified analyses. But from 2013 to now, some new data appearred, differently from the results of previous meta-analyses \[[@R34], [@R37], [@R44]\]. Our study included 10,468 cases and 10,400 controls from 27 independent studies, which is much more than the former three studies. Therefore, the results we obtained might be more stringent and comprehensive.

Our meta-analysis indicated the relationship of *VDR* gene *Fok I* polymorphism with the PCa risk is not existed in overall population. It is consistent with the results of previous meta-analyses \[[@R34], [@R37], [@R44]\]. But for the subgroup analysis of ethnicity, significant association was found in Caucasians. It is not reported by previous meta-analyses \[[@R34], [@R37], [@R44]\]. It suggests that in individuals of Caucasian ethnicity but not of Asians or Africans, the FF genotype and F allele might be protective. Ethnicity is one of the most important biological factors that might influence the function of VDR through gene-gene interaction \[[@R38]\]. The difference might be caused by the discrepancies in racial backgrounds and geography \[[@R40]\]. Besides, different diet structure could play a role in the discrepancies \[[@R41]\]. Our results suggested that the *Fok I* polymorphism could be a potential biomarker to forecast the PCa risk of Caucasians for clinical practice. Further studies of Asian and African are required.

For the source of controls, borderline significant association was found in population-based controls. Possibly some sick population were enrolled in the groups of hospital-based controls and HBP controls, so that these groups could not represent all population \[[@R42]\]. Hence, the results of these groups would be lack of credibility. Our results showed that no difference between the genotyping methods. It suggested that all the genotyping methods applied in the included studies are appropriate to get accurate genotype distribution. As a research reported in 2004, polymorphism would be associated with the tumor stage of PCa \[[@R43]\]. We also performed a stratified analysis by tumor stage. Differently from the previous meta-analyses \[[@R44], [@R45]\], we found that in the subgroup of advanced tumor stage, ff genotype and f allele might increase the PCa risk. It indicating that *Fok I* polymorphism could indeed be a risk factor associated with PCa progression.

The heterogeneity between the studies was very low in the overall analysis. It suggested that the results from these studies were suitable to be pooled \[[@R46]\]. Although evidence of heterogeneity existed in some subgroup analyses, the sensitivity analysis indicated that studies contribute to the heterogeneity did not significantly alter the pooled results. It suggested our results were statistically robust.

Several limitations in our meta-analysis should be acknowledged. First, several studies with small sample size included in our analysis might be underpowered to detect the relationship. Second, our results were according to the unadjusted parameters, a more accurate analysis should be performed, in which the outcomes would be adjusted by some related parameters, including age, dietary status, and other important lifestyle factors.

In conclusion, our meta-analysis might be the largest meta-analysis to estimate the association of *VDR* gene *Fok I* polymorphism with the risk of PCa. Although no significantly association of *Fok I* polymorphism with PCa risk was found in overall population, the possibility of an association in specific subpopulations such as Caucasians and the advanced tumor patients could not be ruled out. In the future, large and well-designed studies are required to illustrate the interactions of *VDR* genetic variants including *Fok I* polymorphism, environmental factors, life style and PCa.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

The PubMed, Embase, Wanfang and Chinese National Knowledge Infrastructure (CNKI) database searches were conducted for all the eligible papers. The following search terms were used: "*VDR*/vitamin D receptor" and "prostate cancer/tumor/carcinoma". Manually searching for the additional studies was conducted according to the references of the original and review reports. The literature search was updated on February, 2016.

Study selection {#s4_2}
---------------

Retrieved studies screened should meet the following criteria: (i) studies on human beings; (ii) in a case-control or nested case-control design; (iii) investigated the association between *VDR gene Fok I* polymorphism and PCa risk; (iv) detailed genotype distribution frequency of cases and controls could be obtained or calculated; (v) and received more than four points in the Newcastle-Ottawa Scale (NOS), which was considered to be high quality.

Data extraction {#s4_3}
---------------

The studies meeting the inclusion criteria were read carefully by two investigators independently (Yansheng Zhao and Lei Wang). The following information was extracted for reaching consensus on all of the items: the first author\'s name, year of publication, country of origin, ethnicity of study population, genotyping methods, source of controls, and number of cases and controls. The subjects were categorized as Asians, African and Caucasians for ethnicity; TaqMan, PCR-RFLP, SNPlex and other subgroup for genotyping method; population-based, hospital-based and Benign Prostate Hyperplasia (BPH) for the source of controls, respectively. We also divided the clinical stages into a localized group and an advanced group. Any disagreements were resolved by a third reviewer (Geng Zhao).

Statistical analysis {#s4_4}
--------------------

A χ^2^-test based on the Q statistic was conducted to assess the heterogeneity. The between-study heterogeneity was considered to be significant when I^2^\>50% and p\<0.1, and the random effects model was chosen to combine values from studies \[[@R11]\]. Otherwise, for homogeneous studies, the fixed effects model was used. The pooled odds ratios (ORs) together with its 95% confidence intervals (95% CIs) were calculated to evaluate the risk. In addition, subgroup analyses were conducted based on ethnicity, genotyping method, source of controls and clinic stages. Sensitivity analysis was performed to assess the stability of pooled results. Begg\'s Funnel plot and Egger\'s test were preformed to assess the potential publication bias. Moreover, Hardy-Weinberg equilibrium (HWE) of controls was reexamined by us with the goodness-of-fit χ^2^-test. All analyses were performed using STATA package version 11.0 (Stata Corp, College Station, TX, USA).
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